Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells
Biotechnology Progress · 2025
DOI: 10.1002/btpr.3506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Progress, 2025. Verfasst von Cristina A T Silva und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemical Engineering, Polytechnique Montréal, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Batch Cell Culture Techniques, SARS-CoV-2, Genetic Vectors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Canadian Foundation for Innovation, Natural Sciences and Engineering Research Council of Canada, Fonds de recherche du Québec - Nature et technologies.
Abstract (Originalsprache)
Vesicular stomatitis virus (VSV) has been increasingly demonstrated as a promising viral vector platform. As the interest over this modality for vaccine and gene therapy applications increases, the need for intensified processes to produce these vectors emerge. In this study, we develop fed‐batch‐based operations to intensify the production of a recombinant VSV‐based vaccine candidate (rVSV‐SARS‐CoV‐2) in suspension cultures of HEK293 cells. A feeding strategy, in which a commercial concentrated medium was added to cultures based on cell growth through a fixed cell specific feeding rate (CSFR), was applied for the development of two different processes using Ambr250 modular bioreactors. Cultures operated in hybrid fed‐batch/perfusion (FB/P) or fed‐batch (FB) were able to sustain infections performed at 8.0 × 10 6 cells/mL, respectively resulting in 3.9 and 5.0‐fold increase in total yield ( Y T ) and 1.7 and 5.6‐fold increase in volumetric productivity (VP) when compared with a batch reference. A maximum viral titer of 4.5 × 10 10 TCID 50 /mL was reached, which is comparable or higher than other processes for VSV production in different cell lines. Overall, our study reports efficient fed‐batch options to intensify the production of a rVSV‐based vaccine candidate in suspension HEK293 cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Chemical Engineering, Polytechnique Montréal, Montreal, Quebec, Canada.
- Department of Bioengineering, McGill University, Montreal, Quebec, Canada.
ORCID-Profile: Cristina A T Silva, Amine A Kamen, Olivier Henry
Förderung
- Canadian Foundation for Innovation
- Natural Sciences and Engineering Research Council of Canada
- Fonds de recherche du Québec - Nature et technologies
Zitieren
APA
Silva, C. A. T., Kamen, A. A., & Henry, O. (2025). Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells. Biotechnology Progress. https://doi.org/10.1002/btpr.3506
Vancouver
Silva CAT, Kamen AA, Henry O. Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells. Biotechnology Progress. 2025. doi:10.1002/btpr.3506
BibTeX
@article{Silva2025,
author = {Silva, Cristina A T and Kamen, Amine A and Henry, Olivier},
title = {Fed‐batch strategies for intensified rVSV vector production in high cell density cultures of suspension HEK293 cells},
journal = {Biotechnology Progress},
year = {2025},
doi = {10.1002/btpr.3506}
}
EUVIMED